A new Chinese expert consensus provides detailed, evidence-graded guidance for managing the hematologic, gastrointestinal, pulmonary, hepatic, neurologic, and ocular side ...
A phase 2 trial found that the HDAC inhibitor entinostat combined with nivolumab produced no tumor responses in advanced cholangiocarcinoma, ...
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!
